Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 8.9% – Should You Sell?

Shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) traded down 8.9% during mid-day trading on Monday. The company traded as low as $3.07 and last traded at $3.07. Approximately 88,257 shares traded hands during trading, a decline of 25% from the average daily volume of 118,054 shares. The stock had previously closed at $3.37.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Armata Pharmaceuticals in a research report on Tuesday, September 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Armata Pharmaceuticals Stock Performance

The stock has a market capitalization of $114.14 million, a P/E ratio of -0.40 and a beta of 1.40. The firm has a 50-day moving average price of $4.43 and a 200 day moving average price of $6.60.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.17. Armata Pharmaceuticals had a negative net margin of 3,467.04% and a negative return on equity of 12.24%. The business had revenue of $2.51 million during the quarter, compared to analyst estimates of $0.40 million. On average, equities analysts anticipate that Armata Pharmaceuticals, Inc. will post 0.50 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Armata Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its stake in shares of Armata Pharmaceuticals by 233.2% in the 1st quarter. Bank of America Corp DE now owns 11,714 shares of the company’s stock worth $120,000 after buying an additional 8,198 shares during the last quarter. Deutsche Bank AG bought a new position in shares of Armata Pharmaceuticals in the second quarter worth $78,000. Bank of New York Mellon Corp bought a new stake in Armata Pharmaceuticals during the second quarter valued at approximately $193,000. Sei Investments Co. bought a new stake in Armata Pharmaceuticals in the 1st quarter worth approximately $760,000. Finally, BlackRock Inc. bought a new position in Armata Pharmaceuticals during the 2nd quarter worth approximately $3,629,000. Institutional investors and hedge funds own 3.57% of the company’s stock.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing bacteriophage-based therapeutics to treat bacterial infections, including infections caused by antibiotic-resistant pathogens. Bacteriophages, or “phages,” are viruses that selectively target and destroy specific bacteria, offering a potential alternative or complement to conventional antibiotics.

The company’s pipeline includes investigational phage therapies for serious respiratory and systemic infections.